

Bile Duct Cancer Drug-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BC07D4B42A8MEN.html>

Date: May 2018

Pages: 146

Price: US\$ 3,480.00 (Single User License)

ID: BC07D4B42A8MEN

Abstracts

Report Summary

Bile Duct Cancer Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bile Duct Cancer Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Bile Duct Cancer Drug 2013-2017, and development forecast 2018-2023

Main market players of Bile Duct Cancer Drug in Europe, with company and product introduction, position in the Bile Duct Cancer Drug market

Market status and development trend of Bile Duct Cancer Drug by types and applications

Cost and profit status of Bile Duct Cancer Drug, and marketing status

Market growth drivers and challenges

The report segments the Europe Bile Duct Cancer Drug market as:

Europe Bile Duct Cancer Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Bile Duct Cancer Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Cabozantinib S-malate

Elpamotide

Exatecan Mesylate

LY-2801653

NUC-1031

Others

Europe Bile Duct Cancer Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Others

Europe Bile Duct Cancer Drug Market: Players Segment Analysis (Company and Product introduction, Bile Duct Cancer Drug Sales Volume, Revenue, Price and Gross Margin):

Ariad Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

Aslan Pharmaceuticals Pte. Ltd.

Bavarian Nordic A/S

Bayer AG

Blueprint Medicines Corporation

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

CellAct Pharma GmbH

Cellceutix Corporation

Cellular Biomedicine Group, Inc.
Concordia Healthcare Corp.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BILE DUCT CANCER DRUG

- 1.1 Definition of Bile Duct Cancer Drug in This Report
- 1.2 Commercial Types of Bile Duct Cancer Drug
 - 1.2.1 Cabozantinib S-malate
 - 1.2.2 Elpamotide
 - 1.2.3 Exatecan Mesylate
 - 1.2.4 LY-2801653
 - 1.2.5 NUC-1031
 - 1.2.6 Others
- 1.3 Downstream Application of Bile Duct Cancer Drug
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Others
- 1.4 Development History of Bile Duct Cancer Drug
- 1.5 Market Status and Trend of Bile Duct Cancer Drug 2013-2023
 - 1.5.1 EMEA Bile Duct Cancer Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Bile Duct Cancer Drug Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Bile Duct Cancer Drug in EMEA 2013-2017
- 2.2 Consumption Market of Bile Duct Cancer Drug in EMEA by Regions
 - 2.2.1 Consumption Volume of Bile Duct Cancer Drug in EMEA by Regions
 - 2.2.2 Revenue of Bile Duct Cancer Drug in EMEA by Regions
- 2.3 Market Analysis of Bile Duct Cancer Drug in EMEA by Regions
 - 2.3.1 Market Analysis of Bile Duct Cancer Drug in Europe 2013-2017
 - 2.3.2 Market Analysis of Bile Duct Cancer Drug in Middle East 2013-2017
 - 2.3.3 Market Analysis of Bile Duct Cancer Drug in Africa 2013-2017
- 2.4 Market Development Forecast of Bile Duct Cancer Drug in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Bile Duct Cancer Drug in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Bile Duct Cancer Drug by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Bile Duct Cancer Drug in EMEA by Types

- 3.1.2 Revenue of Bile Duct Cancer Drug in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Bile Duct Cancer Drug in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Bile Duct Cancer Drug in EMEA by Downstream Industry
- 4.2 Demand Volume of Bile Duct Cancer Drug by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Bile Duct Cancer Drug by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Bile Duct Cancer Drug by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Bile Duct Cancer Drug by Downstream Industry in Africa
- 4.3 Market Forecast of Bile Duct Cancer Drug in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BILE DUCT CANCER DRUG

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Bile Duct Cancer Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 BILE DUCT CANCER DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Bile Duct Cancer Drug in EMEA by Major Players
- 6.2 Revenue of Bile Duct Cancer Drug in EMEA by Major Players
- 6.3 Basic Information of Bile Duct Cancer Drug by Major Players
 - 6.3.1 Headquarters Location and Established Time of Bile Duct Cancer Drug Major Players
 - 6.3.2 Employees and Revenue Level of Bile Duct Cancer Drug Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 BILE DUCT CANCER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Ariad Pharmaceuticals, Inc.

7.1.1 Company profile

7.1.2 Representative Bile Duct Cancer Drug Product

7.1.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Ariad Pharmaceuticals, Inc.

7.2 ArQule, Inc.

7.2.1 Company profile

7.2.2 Representative Bile Duct Cancer Drug Product

7.2.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of ArQule, Inc.

7.3 Array BioPharma Inc.

7.3.1 Company profile

7.3.2 Representative Bile Duct Cancer Drug Product

7.3.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Array BioPharma Inc.

7.4 Arrien Pharmaceuticals, LLC

7.4.1 Company profile

7.4.2 Representative Bile Duct Cancer Drug Product

7.4.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Arrien Pharmaceuticals, LLC

7.5 Aslan Pharmaceuticals Pte. Ltd.

7.5.1 Company profile

7.5.2 Representative Bile Duct Cancer Drug Product

7.5.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Aslan Pharmaceuticals Pte. Ltd.

7.6 Bavarian Nordic A/S

7.6.1 Company profile

7.6.2 Representative Bile Duct Cancer Drug Product

7.6.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bavarian Nordic A/S

7.7 Bayer AG

7.7.1 Company profile

7.7.2 Representative Bile Duct Cancer Drug Product

7.7.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bayer AG

7.8 Blueprint Medicines Corporation

7.8.1 Company profile

7.8.2 Representative Bile Duct Cancer Drug Product

- 7.8.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Blueprint Medicines Corporation
- 7.9 Boehringer Ingelheim GmbH
 - 7.9.1 Company profile
 - 7.9.2 Representative Bile Duct Cancer Drug Product
 - 7.9.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
- 7.10 Boston Biomedical, Inc.
 - 7.10.1 Company profile
 - 7.10.2 Representative Bile Duct Cancer Drug Product
 - 7.10.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Boston Biomedical, Inc.
- 7.11 Bristol-Myers Squibb Company
 - 7.11.1 Company profile
 - 7.11.2 Representative Bile Duct Cancer Drug Product
 - 7.11.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
- 7.12 Celgene Corporation
 - 7.12.1 Company profile
 - 7.12.2 Representative Bile Duct Cancer Drug Product
 - 7.12.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.13 CellAct Pharma GmbH
 - 7.13.1 Company profile
 - 7.13.2 Representative Bile Duct Cancer Drug Product
 - 7.13.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of CellAct Pharma GmbH
- 7.14 Cellceutix Corporation
 - 7.14.1 Company profile
 - 7.14.2 Representative Bile Duct Cancer Drug Product
 - 7.14.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Cellceutix Corporation
- 7.15 Cellular Biomedicine Group, Inc.
 - 7.15.1 Company profile
 - 7.15.2 Representative Bile Duct Cancer Drug Product
 - 7.15.3 Bile Duct Cancer Drug Sales, Revenue, Price and Gross Margin of Cellular Biomedicine Group, Inc.
- 7.16 Concordia Healthcare Corp.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BILE DUCT CANCER DRUG

- 8.1 Industry Chain of Bile Duct Cancer Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BILE DUCT CANCER DRUG

- 9.1 Cost Structure Analysis of Bile Duct Cancer Drug
- 9.2 Raw Materials Cost Analysis of Bile Duct Cancer Drug
- 9.3 Labor Cost Analysis of Bile Duct Cancer Drug
- 9.4 Manufacturing Expenses Analysis of Bile Duct Cancer Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF BILE DUCT CANCER DRUG

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Bile Duct Cancer Drug-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BC07D4B42A8MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC07D4B42A8MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970